By Sanderson Mcleod
•
January 14, 2019
NEWS PROVIDED BY Paul Sanderson January 14, 2019 2018 saw a record amount of private investment in healthcare stocks. We also witnessed multi-billion dollar acquisitions with both BMS and Lilly buying Celgene and Loxo Oncology days before the JP Morgan Healthcare Conference. Our firm was fortunate to work with some of the best and brightest innovators in the market. Clients included Turnstone Biologics , Logic Biotherapeutics , Annexon Biosciences , Endotronix , IGM biosciences , Onconova , Shockwave Medical , Viracta , and Zymeworks . Hires were in numerous functional categories including Chief Medical Officer for Onconova , and SVP of Sales and Marketing for Endotronix. For 2019 we see a number of new modalities gaining traction. With Spark Therapeutics gaining approval for the first gene therapy in the US and EU, and Avexis signing a 8.7 billion dollar deal with Novartis, the road is now well-paved for many others with gene, gene editing and genome editing platforms to move forward. While Kite and Juno, two companies with CAR T platforms, had huge acquisition numbers in 2018, cell therapy in 2019 will expand into other therapeutic applications with Bluerock Therapeutics a company that raised a record a round of $230 million building new medicines in Neurology, Cardiology and Autoimmunity. It is not all about Oncology: While therapeutics in oncology especially immune-oncology have been leading the investment cycle, we started to see expansion into neuroscience with what has been labeled the Neuroscience Renaissance . Companies like Annexon Biosciences , Denali Therapeutics , and Alector have raised huge sums of capital and are poised in 2019 to move forward building medicines for neurodegenerative diseases like Alzheimer’s Huntington’s and Parkinson’s. It is a rare time to be in the biotech industry: Despite the Administration’s plan to cut research dollars for biomedical research utilized by rare disease patients, rare disease biotech’s saw an increase in numbers and we also had some IPOs with Logic Biotherapeutics , Eidos , and Avrobio being a few going out this year. We believe the trend will continue. The patient population is obviously in great need and the path to commercialization is also easier for young companies for a variety of reasons. We look forward to helping find and hire the talent needed for our clients to help them reach their goals bringing better medicines for patients.